INTRODUCTION: Sexual and gender minority individuals (i.e., lesbian, gay, bisexual, and transgender [LGBT]) have a higher smoking prevalence than nonminority individuals. There is limited evidence of smoking abstinence success in nontailored smoking treatments among LGBT smokers. METHODS: This study is a secondary data analysis comparing the efficacy of extended, nontailored treatments among sexual and gender minority and nonminority smokers. Data from two clinical trials were combined to increase power and generalizability of the findings. Trials began with 12 weeks of counseling, nicotine replacement, and bupropion, after which participants were randomized to an extended treatment. RESULTS: Follow-up occurred at weeks 12, 24, 52, 64, and 104. Of the sample (n = 777), 17% identified as sexual and gender minority and 83% as nonminority. The sample was 75% non-Hispanic White, with 86% completing at least some college, and 68% were employed. Sexual and gender minorities were younger and indicated a greater desire to quit smoking than nonminority smokers. No other differences emerged on demographic, smoking, or mood variables. The average Fagerström Test for Nicotine Dependence score was 4.8, and mean daily cigarettes was 19.8. The generalized estimating equations model revealed no significant differences in abstinence between sexual and gender minority smokers and nonminority smokers at all follow-up assessments. CONCLUSIONS: Sexual and gender minority smokers appear as likely to quit or abstain as nonminority smokers in extended, nontailored interventions. However, these findings may not generalize to other geographic areas, where access to treatment is limited or a higher stigma of sexual orientation exists.
INTRODUCTION: Sexual and gender minority individuals (i.e., lesbian, gay, bisexual, and transgender [LGBT]) have a higher smoking prevalence than nonminority individuals. There is limited evidence of smoking abstinence success in nontailored smoking treatments among LGBT smokers. METHODS: This study is a secondary data analysis comparing the efficacy of extended, nontailored treatments among sexual and gender minority and nonminority smokers. Data from two clinical trials were combined to increase power and generalizability of the findings. Trials began with 12 weeks of counseling, nicotine replacement, and bupropion, after which participants were randomized to an extended treatment. RESULTS: Follow-up occurred at weeks 12, 24, 52, 64, and 104. Of the sample (n = 777), 17% identified as sexual and gender minority and 83% as nonminority. The sample was 75% non-Hispanic White, with 86% completing at least some college, and 68% were employed. Sexual and gender minorities were younger and indicated a greater desire to quit smoking than nonminority smokers. No other differences emerged on demographic, smoking, or mood variables. The average Fagerström Test for Nicotine Dependence score was 4.8, and mean daily cigarettes was 19.8. The generalized estimating equations model revealed no significant differences in abstinence between sexual and gender minority smokers and nonminority smokers at all follow-up assessments. CONCLUSIONS: Sexual and gender minority smokers appear as likely to quit or abstain as nonminority smokers in extended, nontailored interventions. However, these findings may not generalize to other geographic areas, where access to treatment is limited or a higher stigma of sexual orientation exists.
Authors: Hao Tang; Greg L Greenwood; David W Cowling; Jon C Lloyd; April G Roeseler; Dileep G Bal Journal: Cancer Causes Control Date: 2004-10 Impact factor: 2.506
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Julie A Robbins; Judith J Prochaska Journal: Addiction Date: 2009-04-09 Impact factor: 6.526
Authors: Allison J Carroll; Amanda R Mathew; Frank T Leone; E Paul Wileyto; Andrew Miele; Robert A Schnoll; Brian Hitsman Journal: Nicotine Tob Res Date: 2020-01-27 Impact factor: 4.244
Authors: Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Kristi E Gamarel; Ethan H Mereish; David Manning; Mariko Iwamoto; Don Operario; Tooru Nemoto Journal: Nicotine Tob Res Date: 2015-03-16 Impact factor: 4.244
Authors: Vani Nath Simmons; Barbara Pineiro; Monica Webb Hooper; Jhanelle E Gray; Thomas H Brandon Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: Sharon M Hall; Yanling Shi; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Judith J Prochaska Journal: Addict Behav Date: 2014-11-20 Impact factor: 3.913
Authors: Erin A Vogel; Johannes Thrul; Gary L Humfleet; Kevin L Delucchi; Danielle E Ramo Journal: Health Psychol Date: 2018-11-29 Impact factor: 4.267
Authors: Alicia K Matthews; Alana D Steffen; Lisa M Kuhns; Raymond A Ruiz; Nat A Ross; Larisa A Burke; Chien Ching Li; Andrea C King Journal: Nicotine Tob Res Date: 2019-10-26 Impact factor: 4.244